Contrea Receives 'Mizuho Innovation Award' and Secures Debt Financing from Mizuho Bank

Contrea Inc. (Headquarters: Shinjuku-ku, Tokyo; CEO: Kazuhiro Kawabata), the operator of the patient-facing DX platform 'MediOS', is pleased to announce its selection as a recipient of the 'Mizuho Innovation Award 2025.3Q', an award presented quarterly by Mizuho Bank to promising innovative companies. Additionally, the company reports that it has successfully secured debt financing from Mizuho Bank.

About the Mizuho Innovation Award The Mizuho Innovation Award was established in 2017 by Mizuho Bank to support the growth of startups challenging themselves with innovative businesses. Companies are selected quarterly based on criteria such as business model superiority, team strength, and growth potential. Recipients receive various support, including business matching with large enterprises, to help accelerate their growth.

Selection Comments from Mizuho Bank 'Contrea’s medical coordination cloud, MediOS, is an innovative solution that achieves high patient comprehension while significantly streamlining physician explanation tasks. We highly evaluate their efforts to simultaneously improve medical workflows and patient satisfaction, contributing to the resolution of the social issue of severe labor shortages in healthcare, as adoption grows in various medical institutions.'

Regarding the Financing from Mizuho Bank Contrea has conducted a funding round through a loan from Mizuho Bank to secure growth capital for business expansion. The raised funds will be used to strengthen products, enhance organizational structure, and develop new business, with the goal of realizing the company's mission: 'Bringing peace of mind to everyone involved in healthcare.'

Comments from Mr. Eiki Uchida, General Manager, Aoyama Corporate Banking Dept., Mizuho Bank 'We evaluate MediOS as a groundbreaking service that not only provides DX support for healthcare professionals but also delivers peace of mind to patients and their families. We are confident that this will lead to solving social issues such as labor shortages on the medical service provider side and an increase in the medical care recipient side due to an aging population, and we intend to continue supporting the company's sustainable growth.'

Comments from Mr. Kazuhiro Kawabata, CEO of Contrea Inc. 'We are deeply honored to be selected for the Mizuho Innovation Award and to have received financing from Mizuho Bank's Aoyama Corporate Banking Department. Japan's medical field is facing a structural crisis of severe labor shortages. Furthermore, in my previous role as a radiographer, I frequently witnessed patients undergoing treatment while anxious due to 'poor communication.' MediOS has grown as a product to solve these issues. To resolve the 'information asymmetry' between medical professionals and patients and to create a world where all patients can undergo medical treatment with conviction, we will expand our organization and continue to evolve our products.'

About Contrea Contrea provides 'MediOS', a patient-facing DX solution that supports end-to-end interactions between healthcare professionals and patients. By simultaneously promoting operational improvement in medical settings and encouraging patient participation, we aim to contribute to sustainable hospital management. MediOS streamlines interactions such as 'medical interviews', 'consent acquisition', 'checking precautions', and 'phone verification', centered on 'patient explanation'. This fundamentally redesigns workflows from repetitive tasks—such as collecting, scanning, and transcribing paper forms, making phone calls, and providing standard explanations—to a system where staff can focus on 'patient care'. We will continue to drive value-driven DX for patients.